Unicycive Therapeutics, Inc.
UNCY
$4.44
-$0.31-6.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -100.00% | -100.00% |
| SG&A Expenses | 90.26% | 70.79% | 41.60% | 28.39% | 35.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.57% | 19.88% | 49.73% | 42.56% | 37.22% |
| Operating Income | -5.57% | -19.88% | -54.60% | -47.42% | -48.72% |
| Income Before Tax | -35.54% | 58.85% | -20.25% | 18.07% | 20.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.54% | 58.85% | -20.25% | 18.07% | 20.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.54% | 58.85% | -20.25% | 18.07% | 20.68% |
| EBIT | -5.57% | -19.88% | -54.60% | -47.42% | -48.72% |
| EBITDA | -5.53% | -19.87% | -54.56% | -47.39% | -48.71% |
| EPS Basic | 59.92% | 110.34% | 60.88% | 62.63% | 62.55% |
| Normalized Basic EPS | 57.40% | 101.25% | 62.26% | 63.96% | 63.88% |
| EPS Diluted | 72.52% | 68.73% | 27.59% | 31.81% | 35.36% |
| Normalized Diluted EPS | 65.12% | 88.40% | 52.35% | 54.81% | 55.84% |
| Average Basic Shares Outstanding | 209.73% | 197.09% | 173.04% | 151.48% | 131.47% |
| Average Diluted Shares Outstanding | 124.78% | 250.79% | 230.34% | 223.28% | 224.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.00% | -- | -- | -- | -- |